

LIQUIDITY CONTRACT: TRANSFER FROM BIL FINANCE TO DSF MARKETS

Paris October 16, 2013

DEINOVE (ISIN : FR0010879056 – ALDEI), whose securities are admitted to trading on Alternext Paris was informed on 1 July 2013 that DSF MARKETS acquired the activities of DFS BIL Finance Markets dated 25 June 2013.

As such, to replace the liquidity contract concluded previously with BIL Finance, the Company DEINOVE has signed a new contract with DSF Markets liquidity that conforms to the Ethics Charter of AMAFI recognized by the "Autorité des Marchés Financiers" (French exchange supervisory authority)

At Stock exchange closing on October 15, 2013, the following assets appeared on the liquidity account:

- Number of shares: 4,230 shares of DEINOVE
- Cash position: € 132,800.30

The same assets have been allowed to the new liquidity contract signed with DSF MARKETS at Stock exchange opening on October 16, 2013.

ABOUT DEINOVE

DEINOVE (Alternext Paris: Aldei) is a biotechnology company that designs and develops new production systems based on bacteria with untapped potential: the *Deinococcus*.

Taking advantage of the unique genetic properties and unusual robustness of *Deinococcus*, the synthetic biology experts at DEINOVE optimize the enzymatic and metabolic capabilities of these natural "micro-factories" to manufacture rare compounds or products that are not achievable using classic chemical and enzymatic processes: second generation bioethanol (DEINOL); enzymes for bioremediation of plastics (THANAPLAST™); new antibiotics (DEINOBIOTICS); terpenoids for chemistry, cosmetics and biopharmaceuticals (DEINOCHEM).

Listed on Alternext since April 2010, DEINOVE was founded by Dr Philippe POULETTY, General Partner of Truffle Capital, and Pr Miroslav RADMAN, Professor at the Faculty of Medicine of the Université René Descartes. With a workforce of about 30 people, it conducts R&D programmes in partnership with the CNRS (Marseille and Montpellier), INSA (Toulouse) and the VTT (Finland). The Company is headquartered in Paris, with laboratories located in the Cap Alpha Technology Park in Montpellier (France).

More information at www.deinove.com

CONTACTS

DEINOVE

Emmanuel PETIOT

CEO

Tel: +33 (0) 1 42 03 27 37

emmanuel.petiot@deinove.com

Headquarters:

22 Rue Léon Jouhaux - 75010 PARIS - France

Tel: +33 (0)1 42 03 27 37 – Fax: +33 (0)1 47 23 54 03

Laboratories :

Cap Alpha, Avenue de l'Europe - 34830 CLAPIERS - France

Julien COSTE

Director of Finance & Administration

Tel: +33 (0) 1 42 03 27 37

julien.coste@deinove.com

